Project Grant R01AG095016
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,178,675 to investigate the spatial organization and conformational ensembles of alpha-synuclein (a-syn) amyloids inside cells. The project aims to identify the prevalent a-syn amyloid conformations and their abundances in biological settings, which could enhance understanding of amyloid propagation and aid in identifying biologically relevant structures. Key objectives include...
- This federal Project Grant award, valued at $1,552,000.00 and provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a research study examining the relationship between markers of vascular and immune dysfunction, such as platelet aggregation and neutrophil levels, and their association with dementia risk and increased Alzheimer's disease (AD) biomarkers. The study, conducted by New York University School of Medicine, aims to integrate biofluid biomarker data with...
- The National Institute on Aging (NIA) awarded a $717,491 Project Grant under its Aging Research program (CFDA 93.866) to New York University (NYU) School of Medicine to develop single domain antibodies (sdAbs) that can detect and clear alpha-synuclein (αSyn) in animal models of synucleinopathies. The project aims to evaluate the in vivo imaging potential, clearance mechanisms, and therapeutic efficacy of these sdAbs targeting αSyn, a key protein involved in neurodegenerative diseases like Lewy...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) will support a $185,074 research study conducted by the University of California, Berkeley. The goal of the study is to examine how brain network connectivity is associated with Alzheimer's disease (AD) risk, longitudinal pathology accumulation, and aging. The researchers will use positron emission tomography (PET) imaging and resting-state functional MRI (rs-fMRI) to investigate the mechanisms of how...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease (PD) and Alzheimer's disease related dementias (ADRD). The $793,535 award, with a project period from December 1, 2024 to November 30, 2029, will fund studies...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $647,116 to the Regents of the University of Michigan to characterize and target a novel pathway promoting Parkinson's disease (PD) and Parkinson's disease dementia (PDD). The funded research aims to investigate how the interaction between the protease tissue...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This $3,360,074 federal Project Grant was awarded on September 15, 2025 by the National Institute on Aging (NIA) under the Aging Research grant program (CFDA 93.866). The grant is funding research led by the University of Pennsylvania to develop short RNA therapeutics that can combat TDP-43 proteinopathy, a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. The research aims to...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $418,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to President and Fellows of Harvard College's Harvard T.H. Chan School of Public Health. The grant will support a comprehensive investigation into the potential role of infections in the development of Parkinson's disease and related non-motor symptoms. The study will leverage data and blood...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,361,361 to Yale University to conduct the "IMMUNOLOGIC AND IMAGING STUDIES WITH TNF THERAPY IN PRODROMAL SYNUCLEINOPATHIES" study. This pioneering, prospective, randomized, double-blind study aims to assess the potential of the anti-TNF drug adalimumab to slow or prevent the emergence of motor and cognitive symptoms of synucleinopathies, such as Parkinson's disease, in 100 subjects with polysomnographically-proven rapid eye movement sleep behavior disorder (RBD). The study will utilize multimodal neuroimaging, wearable biosensors, and in-depth immunophenotyping with single-cell RNA sequencing to characterize the immune cell populations and inflammatory markers in the cerebrospinal fluid of a subset of the participants. The award period runs from September 1, 2025 to August 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.4m | 8/20/25 |